Latest Research Findings on Prediction of Preeclampsia in Pregnant Women Based on Analysis of Cell-Free RNA in Peripheral Blood

SHUI Li-ping, XU Wen-ming, HE Guo-lin

Abstract

Preeclampsia gravely threatens the health of mothers and infants. At present, treatment based on the relevant mechanisms of pathogenesis is still not available, and there is no independent reliable clinical index for early prediction of preeclampsia. According to recent studies, analysis of the cell-free RNA in the peripheral blood of pregnant women has shown that testing certain cell-free RNA levels can help predict in advance the occurrence of preeclampsia before clinical symptoms appear. In this paper, we described the status of research and progress in using maternal cell-free RNA analysis in predicting preeclampsia. In addition, we stated that cell-free RNA in peripheral blood may become a promising, real-time and non-invasive monitoring method that can be used to explore the mechanisms of pathogenesis and pathophysiology of preeclampsia and to identify different subtypes of preeclampsia.

 

Keywords: Cell-free RNA, Prediction of preeclampsia, Maternal cell-free RNA, Cell-free fetal RNA

 

Full Text:

PDF


References


RANA S， LEMOINE E， GRANGER J P， et al. Preeclampsia: Pathophysiology, challenges, and perspectives. Circ Res，2019，124(7): 1094–1112.

PANKIEWICZ K， SZCZERBA E， MACIEJEWSKI T， et al. Non-obstetric complications in preeclampsia. Prz Menopauzalny，2019，18(2): 99–109.

BURGER R J， DELAGRANGE H， VAN VALKENGOED I G M， et al. Hypertensive disorders of pregnancy and cardiovascular disease risk across races and ethnicities: A review. Front Cardiovasc Med， 2022， 9: 933822[2022-06-20]. https://doi.org/10.3389/fcvm.2022.933822.

ABALOS E， CUESTA C， GROSSO A L， et al. Global and regional estimates of preeclampsia and eclampsia: A systematic review. Eur J Obstet Gynecol Reprod Biol，2013，170(1): 1–7.

STAFF A C. The two-stage placental model of preeclampsia: An update. J Reprod Immunol，2019，134-135: 1–10.

OPICHKA M A， RAPPELT M W， GUTTERMAN D D， et al. Vascular dysfunction in preeclampsia. Cells，2021，10(11): 3055.

ROLNIK D L， WRIGHT D， POON L C Y. et al ASPRE trial: performance of screening for preterm pre-eclampsia. Ultrasound Obstet Gynecol，2017，50(4): 492–495.

MACDONALD TM， WALKER SP， HANNAN NJ， et al. Clinical tools and biomarkers to predict preeclampsia. EBioMedicine， 2022， 75: 103780[2022-06-20]. https://doi.org/10.1016/j.ebiom.2021.103780.

CHAEMSAITHONG P， SAHOTA D S， POON L C. First trimester preeclampsia screening and prediction. Am J Obstet Gynecol， 2022， 226(2S): S1071−S1097. e2[2022-06-20]. https://doi.org/10.1016/j.ajog. 2020.07.020.

ADEFISAN A S， AKINTAYO A A， AWOLEKE J O， et al. Role of second-trimester uterine artery Doppler indices in the prediction of adverse pregnancy outcomes in a low-risk population. Int J Gynaecol Obstet，2020，151(2): 209–213.

LEVINE R J， MAYNARD S E， QIAN C， et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med，2004，350(7): 672–683.

ZEISLER H， LLURBA E， CHANTRAINE F， et al. Predictive value of the sFlt-1: PlGF ratio in women with suspected preeclampsia. N Engl J Med， 2016，374(1): 13–22.

MOUFARREJ M N， VORPERIAN S K， WONG R J， et al. Early prediction of preeclampsia in pregnancy with cell-free RNA. Nature， 2022，602(7898): 689–694.

RASMUSSEN M， REDDY M， NOLAN R， et al. RNA profiles reveal signatures of future health and disease in pregnancy. Nature，2022， 601(7893): 422–427.

WEINER C P， DONG Y， ZHOU H， et al. Early pregnancy prediction of spontaneous preterm birth before 32 completed weeks of pregnancy using plasma RNA: Transcriptome discovery and initial validation of an RNA panel of markers. BJOG，2021，128(11): 1870–1880.

WEINER C P， CUCKLE H， WEISS M L， et al. Evaluation of a maternal plasma rna panel predicting spontaneous preterm birth and its expansion to the prediction of preeclampsia. Diagnostics (Basel)，2022，12(6): 1327.

POON L L， LEUNG T N， LAU T K， et al. Presence of fetal RNA in maternal plasma. Clin Chem，2000，46(11): 1832–1834.

NG E K， TSUI N B， LAU T K， et al. mRNA of placental origin is readily detectable in maternal plasma. Proc Natl Acad Sci U S A，2003，100(8): 4748–4753.

KOH W， PAN W， GAWAD C， et al. Noninvasive in vivo monitoring of tissue-specific global gene expression in humans. Proc Natl Acad Sci U S A，2014，111(20): 7361–7366.

SU S， YANG F， ZHONG L， et al. Circulating noncoding RNAs as early predictive biomarkers in preeclampsia: A diagnostic meta-analysis. Reprod Biol Endocrinol，2021，19(1): 177.

SUN N， QIN S， ZHANG L， et al. Roles of noncoding RNAs in preeclampsia. Reprod Biol Endocrinol，2021，19(1): 100.

NG E K， LEUNG T N， TSUI N B， et al. The concentration of circulating corticotropin-releasing hormone mRNA in maternal plasma is increased in preeclampsia. Clin Chem，2003，49(5): 727–731.

ETESAMI E， NIKUKAR H， RAMEZANALI F. et al Gene expression analysis of MMPs in women with preeclampsia using cell-free fetal RNA in maternal plasma. Pregnancy Hypertens，2019，17: 261–268.

WHIGHAM C A， MACDONALD T M， WALKER S P. et al Circulating adrenomedullin mRNA is decreased in women destined to develop term preeclampsia. Pregnancy Hypertens，2019，16: 16–25.

TAN M Y， SYNGELAKI A， POON L C， et al. Screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation. Ultrasound Obstet Gynecol，2018，52(2): 186–195.

LIANG Z， WANG L. Expression and clinical significance of lncRNA NORAD in patients with gestational hypertension. Ginekol Pol， 2022[2022-07-20]. https://doi.org/10.5603/GP.a2022.0016.

SUN Y， HOU Y， LV N， et al. Circulating lncRNA BC030099 increases in preeclampsia patients. Mol Ther Nucleic Acids，2019，14: 562–566.

WANG R， ZOU L， YANG X. microRNA-210/Long non-coding RNA MEG3 axis inhibits trophoblast cell migration and invasion by suppressing EMT process. Placenta，2021，109: 64–71.

OGOYAMA M， TAKAHASHI H， SUZUKI H， et al. Non-coding RNAs and prediction of preeclampsia in the first trimester of pregnancy. Cells， 2022，11(15): 2428.

XU X， TENG H. circRNA circ_0055724 inhibits trophoblastic cell line HTR-8/SVneo's invasive and migratory abilities via the miR-136/N-Cadherin axis. Dis Markers， 2022， 2022: 9390731[2022-06-20]. https://doi.org/10.1155/2022/9390731.

HU X， AO J， LI X， et al. Competing endogenous RNA expression profiling in pre-eclampsia identifies hsa circ 0036877 as a potential novel blood biomarker for early pre-eclampsia. Clin Epigenetics， 2018， 10: 48[2022-06-20]. https://doi.org/10.1186/s13148-018-0482-3.

LIU J， YANG Y， LIU W， et al. circ_0085296 inhibits the biological functions of trophoblast cells to promote the progression of preeclampsia via the miR-942-5p/THBS2 network. Open Med (Wars)，2022，17(1): 577–588.

JIANG M， LASH G E， ZHAO X， et al. CircRNA-0004904, circRNA-0001855, and PAPP-A: Potential novel biomarkers for the prediction of preeclampsia. Cell Physiol Biochem，2018，46(6): 2576–2586.

YOFFE L， GILAM A， YARON O， et al. Early detection of preeclampsia using circulating small non-coding RNA. Sci Rep，2018，8(1): 3401.

JIN M， XU Q， LI J， et al. Micro-RNAs in human placenta: Tiny molecules, immense power. Molecules，2022，27(18): 5943.

TANG J， WANG D， LU J， et al. MiR-125b participates in the occurrence of preeclampsia by regulating the migration and invasion of extravillous trophoblastic cells through STAT3 signaling pathway. J Recept Signal Transduct Res，2021，41(2): 202–208.

KUMAR P， LUO Y， TUDELA C， et al. The c-Myc-regulated microRNA-17～92 (miR-17～92) and miR-106a～363 clusters target hCYP19A1 and hGCM1 to inhibit human trophoblast differentiation. Mol Cell Biol，2013，33(9): 1782–1796.

WANG W， FENG L， ZHANG H， et al. Preeclampsia up-regulates angiogenesis-associated microRNA (i.e. ， miR-17， -20a， and -20b) that target ephrin-B2 and EPHB4 in human placenta. J Clin Endocrinol Metab， 2012， 97(6): E1051–E1059[2022-06-20]. https://doi.org/10.1210/jc.2011-3131.

ABDELAZIM S A， SHAKER O G， ALY Y A H， et al. Uncovering serum placental-related non-coding RNAs as possible biomarkers of preeclampsia risk, onset and severity revealed MALAT-1, miR-363 and miR-17. Sci Rep，2022，12(1): 1249.

ANTON L， OLARERIN-GEORGE A， SCHWARTZ N， et al. miR-210 inhibits trophoblast invasion and is a serum biomarker for preeclampsia. Am J Pathol，2013，183(5): 1437–1445.

LI H， OUYANG Y， SADOVSKY E， et al. Unique microRNA signals in plasma exosomes from pregnancies complicated by preeclampsia. Hypertension，2020，75(3): 762–771.

MOTAWI T M K， SABRY D， MAURICE N W， et al. Role of mesenchymal stem cells exosomes derived microRNAs; miR-136, miR-494 and miR-495 in pre-eclampsia diagnosis and evaluation. Arch BiochemBiophys，2018，659: 13–21.

HROMADNIKOVA I， KOTLABOVA K， IVANKOVA K， et al. First trimester screening of circulating C19MC microRNAs and the evaluation of their potential to predict the onset of preeclampsia and IUGR. PLoS One， 2017， 12(2): e0171756[2022-6-20]. https://doi.org/10.1371/journal. pone.0171756.

PILLAY P， VATISH M， DUARTE R， et al. Exosomal microRNA profiling in early and late onset preeclamptic pregnant women reflects pathophysiology. Int J Nanomedicine，2019，14: 5637–5657.

SALOMON C， RICE G E. Role of exosomes in placental homeostasis and pregnancy disorders. Prog Mol Biol Transl Sci，2017，145: 163–179. TANNETTA D， MASLIUKAITE I， VATISH M， et al. Update of syncytiotrophoblast derived extracellular vesicles in normal pregnancy and preeclampsia. J Reprod Immunol，2017，119: 98–106.

SINGH K， WILLIAMS J 3rd， BROWN J， et al. Up-regulation of microRNA-202-3p in first trimester placenta of pregnancies destined to develop severe preeclampsia, a pilot study. Pregnancy Hypertens，2017， 10: 7–9.


Refbacks

  • There are currently no refbacks.